Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Constance Thibault1

  • 1Service d'oncologie médicale, Hôpital Européen Georges-Pompidou, Paris, France.

Bulletin Du Cancer
|January 1, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making.

European urology oncology·2026
Same author

Evaluating the Surrogacy of Pathological Complete Response at Radical Cystectomy in Neoadjuvant-based Muscle-invasive Bladder Cancer Trials.

European urology oncology·2026
Same author

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study.

Cancer immunology, immunotherapy : CII·2026
Same author

Robot-Assisted Versus Open Bladder Cuff Excision After Radical Nephroureterectomy: A Multicenter Study by the French Urothelial Cancer Committee.

Annals of surgical oncology·2026

Immunotherapies, including immune-checkpoint inhibitors, offer new hope for bladder cancer treatment. This review covers ongoing trials and combination therapies for urothelial carcinoma.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Limited therapeutic progress in bladder cancer over the past 30 years.
  • Emergence of immunotherapy as a promising treatment modality in the 21st century.

Purpose of the Study:

  • To review clinical data from ongoing immunotherapeutic trials for urothelial carcinoma.
  • To explore the combination of immunotherapies with chemotherapy, antiangiogenics, and radiotherapy.

Main Methods:

  • Review of clinical data from immunotherapeutic trials.
  • Analysis of ongoing studies involving checkpoint inhibitors, vaccines, and cytokines.
  • Examination of combination therapy approaches.

Main Results:

  • Immunotherapies, particularly immune-checkpoint inhibitors, show promising early trial results.
Keywords:
CarcinomesImmune checkpointImmunotherapyImmunothérapieInhibiteursUrothelial carcinomaVaccinVaccinede checkpointsimmunologiquesinhibitorsurothéliaux

Related Experiment Videos

  • Potential for new therapies to be integrated into urothelial carcinoma treatment.
  • Investigating synergistic effects of combining immunotherapies with other treatment modalities.

    • Conclusions:

    • Immunotherapies represent a significant advancement in bladder cancer treatment.
    • Combination strategies may enhance the efficacy of urothelial carcinoma therapies.
    • Future treatment landscape for urothelial carcinoma is expected to evolve with immunotherapy.